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ABSTRACT
Introduction: Use of prediction matrices of risk or
rapid radiographic progression (RRP) for early
rheumatoid arthritis (RA) in clinical practice could help
to better rationalise the first line of treatment. Before
use, they must be validated in populations that have not
participated in their construction. The main objective is
to use the ESPOIR cohort to validate the performance
of 3 matrices (ASPIRE, BEST and SONORA) to predict
patients at high risk of RRP at 1 year of disease despite
initial treatment with methotrexate (MTX).
Methods: We selected from the ESPOIR cohort 370
patients receiving MTX or leflunomide (LEF) for
≥3 months within the first year of follow-up. Patients
were assessed clinically every 6 months, and structural
damage progression seen on radiography was
measured by the van der Heijde-modified Sharp score
(vSHS) at 1 year. RRP was defined as an increase in
the vSHS≥5 points during the first year.
Results: At 1 year, the mean vSHS score was 1.7±5.0
and 46 patients had RRP. The ASPIRE matrix had only
moderate validity in the ESPOIR population, with area
under the receiver operating characteristic curve (AUC)
<0.7. The AUC for the BEST and SONORA matrices
were 0.73 and 0.76. Presence of rheumatoid factor
(RF)—or anti-citrullinated protein antibodies (ACPAs)
and initial structural damage were always predictive of
RRP at 1 year. Disease Activity Score in 28 joints
(DAS28) and C reactive protein (ASPIRE threshold)
were not associated with RRP.
Conclusions: Matrices to identify patients at risk of
RRP tested in the ESPOIR cohort seem to perform
moderately. There is no matrix that shows clearly
superior performance.
INTRODUCTION
During the past decade, the standard of care
for early rheumatoid arthritis (RA) has
evolved greatly, combining early referral to
the rheumatologist to hasten the RA diagno-
sis,1–3 initiation of rapid disease-modifying
anti-rheumatic drugs (DMARDs) within the
‘window of opportunity’1 2 and tight control
of disease activity based on regular DMARD
adaptation according to the ‘treat to target’
strategy.2 4–6
The choice of the ﬁrst DMARD may be
important for RA prognosis and has been
addressed by many trials and guidelines.
Synthetic DMARDs (sDMARDs) such as
methotrexate (MTX) or leﬂunomide (LEF)
are the most recommended as ‘anchor’ ther-
apies because they can be associated with
other synthetic or biological DMARDs
(bDMARDs) according to the response to
Key messages
What is already known about this subject?
▸ Rapid radiographic progressor matrices can
identify early rheumatoid arthritis patients with
high risk of structural damage progression
despite initiation of methotrexate.
What does this study add?
▸ The present study validates the good perform-
ance of the 3 matrices (BEST, SONORA and
ASPIRE) in another population of early RA
patients.
How might this impact on clinical practice?
▸ Rapid radiographic progression matrices are
valuable tools to optimise the care of early RA
patients by choosing more aggressive therapy
than MTX alone.
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initial monotherapy.2 7–9 Additionally, some studies sug-
gested that use of sDMARDs tritherapy or bDMARDs as
ﬁrst-line agents could be efﬁcacious to rapidly achieve
remission and block structural damage.2 9–13 However,
safety concerns and the high costs of biologics appear to
limit their use for early RA. Several economic evalua-
tions reported that incremental cost-effectiveness ratios
of biologics as ﬁrst-line treatment for early RA are
usually high and largely surpass the generally accepted
thresholds.14 15
If biological agents are not recommended for all
patients with early RA, they may still be of interest for
patients with poor prognostic factors and features of
severe disease, for whom MTX is most likely insufﬁ-
cient.2 5 Several trials have shown substantial structural
progression in a small subset of patients despite rapid
initiation of MTX therapy, which led to the development
of the concept of rapid radiographic progression (RRP)
to identify such patients. RRP is deﬁned as structural
damage progression by an increase in the van der
Heijde-modiﬁed Sharp score (vSHS) ≥5 points over
1 year; the cut-off of 5 points corresponds to the destruc-
tion of one small joint and to the usually reported smal-
lest detectable difference (SDD).16–18 The rationale for
RRP patient identiﬁcation has been validated in two dif-
ferent studies. In the BEST trial, patients with RRP
during the ﬁrst year of follow-up showed increased func-
tional limitations and structural damage progression
over 8 years of follow-up, despite a tightly controlled
therapeutic strategy.18 These results were consistent with
another study of the ESPOIR cohort, in which patients
with RRP during the ﬁrst year in the cohort—with a def-
inition slightly different from the previous one—showed
increased structural damage progression during the
second and third years in the cohort.19
Patient risk stratiﬁcation with regard to RRP has
become highly important and has been addressed by
the development of prediction matrices to quantify the
risk of RRP at 1 year of follow-up. RRP matrices, based
on the same methodology used in cardiology or osteo-
porosis,20 21 were developed within randomised control
trials (RCTs)16 22 23 or observational cohorts24–26 and
have involved different sets of baseline characteristics to
calculate, at the patient level, the probability of a given
patient showing RRP on a 1 year radiograph despite
MTX therapy (ie, the probability of being a radiographic
MTX inadequate responder). The matrices differ by the
nature of the components they use, their thresholds and
how they take into account structural damage. These
tools have rarely been validated in populations different
from those for which they were developed. The only vali-
dations were performed with the BRASS cohort, which
included patients with established RA,27 and in a cohort
of patients with DMARD-naïve early RA recruited at the
Department of Rheumatology of the University
Hospitals Leuven.25 28 The substantial differences
between established and early RA resulted in low per-
formance of the three tested matrices (ASPIRE, BEST
and SWEFOT). Therefore, additional validation was
needed (bigger cohort, extra matrix—SONORA), which
is possible with the ESPOIR cohort. The ESPOIR cohort
enrolled patients with early arthritis from the commu-
nity (with or without unfavourable prognostic factors),
most receiving MTX or LEF as ﬁrst-line treatment.
In this study, we aimed to test the performance and
validity of the different published RRP prediction matri-
ces in patients with early RA from the ESPOIR cohort.
METHODS
We aimed to assess the performance of different predic-
tion matrices that were developed to identify patients
with early RA at substantial risk of rapid structural
damage progression, deﬁned as an increase in the
vSHS≥5 points between baseline and the 1 year
follow-up visit.
Previously published matrices
The patient characteristics in the tested matrices are in
online supplementary materials—table 1. Three matrices
were developed with RCT populations, all testing the
efﬁciency of a combination of MTX+inﬂiximab versus
MTX monotherapy in patients with early RA:
ASPIRE,16 29 SWEFOT23 30 and BEST.22 31 In these
studies, we only used the matrix developed for patients
of the MTX arm. All trials used the same deﬁnition of
RRP: an increase in the vSHS≥5 points within the ﬁrst
year after treatment initiation, which theoretically corre-
sponds to the destruction of one joint based on vSHS
scoring17 or also ﬁve new small erosions in ﬁve different
joints, or an association of progression in erosion lesions
and joint space narrowing. In addition, we used the
SONORA matrix based on data for a North American
observational cohort of 994 patients with early RA who
received a sDMARD.24 In this study, RRP deﬁnition was
an increase in the vSHS≥3.54 points, which was the
SDD. We also used the original ESPOIR matrix as well as
a modiﬁed version (mESPOIR matrix) developed with
the same methodology.26 Although the original ESPOIR
matrix assessed structural damage qualitatively—‘typical
RA erosion’, yes or no—the mESPOIR matrix used a
quantitative vSHS-based assessment for structural
damage, categorised in three classes (<5 points, 5–14
points, >14 points). For these two matrices, RRP was
deﬁned as an increase in the vSHS≥5 points.
Validation population
The protocol for the ESPOIR cohort study was approved
by the Ethics Committee of Montpellier University
Hospital, France. All patients gave their signed informed
consent to participate in the cohort. Between December
2002 and March 2005, 813 patients with possible RA
who were referred by rheumatologists and general prac-
titioners to one of 14 regional centres were included in
the ESPOIR cohort.32 33 Inclusion criteria were age 18–
70 years, more than two swollen joints for >6 weeks and
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<6 months, suspected or conﬁrmed diagnosis of RA, and
not taking any DMARDs or steroids except for <2 weeks
before enrolment. During the ﬁrst year, patients were
followed every 6 months. At each time point, data were
collected on disease activity by the Disease Activity Score
in 28 joints (DAS28),34 functional ability by the Health
Assessment Questionnaire (HAQ),35 radiography of the
hand and foot (anteroposterior views) and therapeutic
regimen. Treatment strategies were not protocol-based
in the ESPOIR cohort, and patients received usual care
by their rheumatologist.
This study involved data for ESPOIR patients with an
RA diagnosis according to their rheumatologist and initi-
ation of a ﬁrst sDMARD such as MTX or LEF with
demonstrated structural efﬁcacy for at least 3 months
during the ﬁrst year of follow-up in the cohort. Patients
who initially received MTX started the drug 27.2±15.1
weeks after disease onset. Those who initially received
LEF received it 30.1±18.1 weeks after disease onset.26
Treatment duration was 37.2±12.3 (39.4) weeks during
the ﬁrst year for patients under MTX and 39.6±13.5
(43.1) for patients under LEF. No statistical difference
between RRP+ and RRP− patients was found for treat-
ment duration. Some patients received insufﬁcient
dosage of another treatment (as other sDMARD or
bDMARD);26 this point has not been considered in the
analysis. As detailed elsewhere,26 radiographs were read
pairwise by a well-trained investigator blinded to clinical
evaluation (intraclass correlation coefﬁcient 0.99, SDD
0.966).6 Structural damage was assessed qualitatively by
the presence of typical RA erosions, based on their loca-
tion and aspect, and quantiﬁed by the vSHS.36 37 RRP
was deﬁned as change in vSHS (ΔvSHS) ≥5 at
1 year.16 18 22 26
Statistical analysis
Baseline characteristics and disease evolution were
described for all patients and by RRP status by mean±SD
(median) or frequency (percentage) as appropriate
(table 1). Baseline characteristics and disease evolution
were compared between RRP+ and RRP− by
Mann-Whitney U test (for numerical data) and Fisher’s
exact test (for categorical data) (table 1). To test the
relevance of RRP predictors used with the previous
cohorts, we used Fisher’s exact test for univariate ana-
lysis, then logistic regression analysis to determine pre-
dictors of RRP as the outcome variable (table 2).
The performance of previously published RRP matri-
ces (BEST, SONORA, ASPIRE) with patients with early
RA from the ESPOIR cohort was tested by several statis-
tics (table 3). The SWEFOT matrix was not tested due to
lack of information about the model parameters estima-
tion available in the reference article. Two models were
used for each previously published matrix. The ﬁrst was
based on only the published values of the different esti-
mated parameters (intercept and regression coefﬁ-
cients). The second was recalibrated (with a new
estimate of the intercept, the regression coefﬁcients
Table 1 Baseline characteristics and disease evolution of the ESPOIR patients who received MTX or its equivalent, LEF, as
a first-line biologic agent for RA, and radiographic structural damage progression during the first year in the cohort
ESPOIR cohort patients who received MTX or LEF
Characteristics All (n=370) RRP+ (n=41) RRP− (n=329)
Age, years 49.4±11.4 (51.5) 50.2±10.8 (52.1) 49.3±11.5 (51.4)
Female sex 271 (73.2%) 31 (75.6%) 240 (73%)
Disease duration, weeks* 15.2±8.2 (13.6) 18.6±8.4 (18.6) 14.7±8.1 (13)
2010 ACR/EULAR criteria 316 (85.4%) 38 (92.7%) 278 (84.5%)
Swollen joint count in 28 joints 7.9±5.4 (7) 8.7±6.1 (8) 7.8±5.3 (7)
Tender joint count in 28 joints 8.7±6.9 (7) 8.3±6.3 (7) 8.7±6.9 (7)
ESR, mm/1st h 32.7±25 (26) 32.6±21.0 (30) 32.7±25.4 (25)
CRP, mg/L 24.8±37.7 (11) 26.0±27.9 (14) 24.6±38.7 (11)
DAS28 5.3±1.2 (5.2) 5.3±1.2 (5.4) 5.3±1.2 (5.2)
IgM RF positivity* 204 (55.1%) 29 (70.7%) 175 (53.2%)
ACPA positivity* 185 (50%) 31 (75.6%) 154 (46.8%)
HAQ score 1.0±0.7 (1) 1.0±0.6 (1) 1.0±0.7 (1)
Typical RA erosion 66 (17.8%) 18 (44%) 48 (14.6%)
Duration of DMARD during first year, months 9.06± (3.07) 9.07± (3.20) 8.98± (3.06)
Concomitant glucocorticoids 98 (26%) 7 (17.1%) 91 (27.7%)
vSHS baseline total score* 4.5±6.8 (2) 10.8±9.8 (9) 3.7±5.8 (2)
ΔvSHS total 1.6±5.4 (0) 12.9±8.0 (10) 0.2±2.8 (0)
Progressors (ΔvSHS≥1) 126 (34.1%) 41 (100%) 85 (25.8%)
*Significant difference between RRP+ and RRP− (p value <0.05).
Data are mean±SD (median) or no. (%).
ACPA, anti-citrullinated protein antibody (ELISA, DiaSorin, France; positive >50 U/mL); ACR/EULAR, American College of Rheumatology/
European League Against Rheumatism; CRP, C reactive protein (normally <10 mg/L); DAS28, Disease Activity Score in 28 joints; DMARD,
disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; LEF, leflunomide; MTX,
methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor (ELISA, Menarini, France; positive >9 UI/mL); RRP, rapid radiographic
progression; vSHS, van der Heijde-modified Sharp score.
Granger B, et al. RMD Open 2016;2:e000245. doi:10.1136/rmdopen-2016-000245 3
Rheumatoid arthritis
group.bmj.com on May 25, 2016 - Published by http://rmdopen.bmj.com/Downloaded from 
remaining the same) on a subsample of the ESPOIR
cohort population, representing one-third of the total
population, to take into account a possible systematic
error of prediction. Then their performance was esti-
mated on the remaining two-thirds of the population.
The likelihood of the ﬁt of models was assessed by the
Bayesian information criteria. The overall signiﬁcance of
the model was assessed by computation of the
Nagelkerke pseudo-R2. The calibration of the model was
assessed by the Hosmer-Lemeshow goodness-of-ﬁt test by
comparing the expected and observed event rates in
subgroups of the population (deciles); a signiﬁcant p
value indicated that the model did not ﬁt the observed
data. The calibration assessed the degree of agreement
between the predicted and observed probability. The dis-
criminatory property was tested by the area under the
receiver operating characteristic curve (AUC) of sensitiv-
ity versus 1-speciﬁcity as a predictive model to identify
cases (RRP+) and non-cases (RRP−). The 95% CI of the
AUC was estimated with a bootstrap procedure based on
1000 replications. The mean predicted probability was
calculated for cases (RRP+) and non-cases (RRP−). The
discriminatory ability of the models was tested pairwise
for each model relative to the ESPOIR model by the
integrated discrimination improvement statistic calcu-
lated as: (average predicted probability cases—average predicted
probability controls)new model—(average predicted probability
cases—average predicted probability controls)original ESPOIR model.
Table 2 Association of the previously published matrix determinants with RRP status on univariate and multivariate analysis
Univariate analysis Multivariate analysis
RRP+ (n=41) RRP− (n=329) p Value Estimate SE p Value
ESPOIR matrix
Swollen joint count 14–20 6 (14.6) 32 (9.7) 0.08 0.28 0.53 0.60
Swollen joint count >20 4 (9.8) 12 (3.7) 1.25 0.68 0.07
CRP<35 mg/L 25 (61.0) 168 (51.1) 0.04 0.83 0.57 0.15
CRP ≥35 mg/L 12 (29.3) 72 (21.9) 0.86 0.63 0.17
ACPA positivity 31 (75.6) 154 (46.8) 0.0007 1.11 0.40 0.006
Typical RA erosion 18 (43.9) 48 (14.6) <0.0001 1.31 0.37 0.0004
mESPOIR matrix
Swollen joint count >13 10 (24.4) 44 (13.4) 0.09 0.89 0.46 0.05
ACPA positivity 31 (75.6) 154 (46.8) 0.0007 1.22 0.41 0.003
Baseline SHS 5–14 19 (46.3) 48 (14.6) <0.0001 2.15 0.41 <0.0001
Baseline SHS>14 10 (24.4) 18 (5.5) 2.34 0.51 <0.0001
SONORA matrix
DAS28≤3.2 2 (4.9) 14 (4.3) 0.69 0.41 0.87 0.64
ACPA≤20 UI/L 10 (24.4) 170 (51.7) 0.001 −1.09 0.40 0.007
Baseline vSHS=0 3 (7.3) 112 (34.0) <0.0001 −2.80 0.67 <0.0001
Baseline vSHS=1–5 9 (21.9) 151 (45.9) −1.97 0.47 <0.0001
Baseline vSHS=6–10 13 (31.7) 32 (9.7) −0.06 0.46 0.90
ASPIRE matrix
Swollen joint count 10–17 11 (26.8) 79 (24.0) 0.72 0.25 0.40 0.54
Swollen joint count ≥17 4 (9.8) 26 (7.9) 0.45 0.60 0.45
CRP 6–30 mg/L 21 (51.2) 134 (40.7) 0.09 0.92 0.48 0.06
CRP≥30 mg/L 13 (31.7) 84 (25.5) 1.41 0.61 0.02
ESR 21–50 mm/1st h 18 (43.9) 107 (32.5) 0.37 −0.07 0.42 0.86
ESR ≥50 mm/1st h 8 (19.5) 81 (24.6) −1.03 0.60 0.09
RF 80–200 UI 6 (14.6) 23 (7.0) 0.02 1.08 0.52 0.04
RF≥200 UI 10 (24.4) 42 (12.8) 0.97 0.43 0.02
BEST matrix
CRP 10–35 mg/L 13 (31.7) 108 (32.8) 0.55 0.03 0.43 0.95
CRP≥35 mg/L 12 (29.3) 72 (21.9) 0.11 0.44 0.81
RF+ or ACPA+ 4 (9.8) 51 (15.5) 0.007 0.05 0.65 0.94
RF+ and ACPA+ 28 (68.3) 139 (42.2) 0.94 0.43 0.03
Radiographic erosions 1–3 8 (19.5) 123 (37.4) <0.0001 0.75 0.63 0.23
Radiographic erosions ≥4 29 (70.7) 73 (22.2) 2.48 0.56 <0.0001
SWEFOT matrix
Current smoker 14 (34.1) 158 (48.0) 0.09 −0.51 0.36 0.15
CRP 10–35 mg/L 13 (31.7) 108 (32.8) 0.55 0.03 0.41 0.94
CRP≥35 mg/L 12 (29.3) 72 (21.9) 0.32 0.42 0.46
Radiographic erosions 18 (43.9) 48 (14.6) <0.0001 1.47 0.35 <0.0001
ACPA, anti-citrullinated protein antibody; CRP, C reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation
rate; RA, rheumatoid arthritis; RF, rheumatoid factor; RRP, rapid radiographic progression; vSHS, van der Heijde-modified Sharp score.
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A positive value indicated that the new model provided
an improvement over the original ESPOIR model. The p
values were calculated as described by Pencina et al.36
For each model, the observed probability of RRP was
plotted for groups of participants by predicted probabil-
ity of RRP. The groups in the model were deﬁned by
cut-offs for quartiles of predicted probability of RRP;
therefore, owing to a large number of equivalent values,
the construction of four groups led to large differences
in the number of participants in each group. The plots
represent the observed proportion of RRP and the 95%
CI by group.
All analyses involved the use of R 2.15.2 for Windows
(R Foundation, Vienna, Austria).
RESULTS
Patient characteristics
The selected patients have been described elsewhere.26
Brieﬂy, 370 patients (45.5%) from the initial ESPOIR
cohort started MTX (n=335, mean dose 17.5 mg/week)
or LEF (n=35, mean dose 20 mg/week) as ﬁrst-line
DMARDs, referred to as ‘sDMARD-treated patients’. No
statistical difference was found for the treatment dose
between RRP+ and RRP− patients. Their main
characteristics are given in table 1. Among the 126
patients (34.1%) with disease progression (ie, ΔvSHS≥1
(SDD)), 41 had RRP (ie, ΔvSHS≥5), representing 11.1%
of all sDMARD-treated patients and 32.5% of patients
with disease progression. Baseline characteristics
between RRP+ and RRP− were signiﬁcantly different for
disease duration, which was longer for RRP+ than RRP−
patients. Signiﬁcant differences were found concerning
the IgM rheumatoid factor (RF) positivity and the anti-
citrullinated protein antibodies (ACPAs) positivity with a
more frequent positivity among RRP+. Another signiﬁ-
cant difference is found concerning the baseline score
vSHS with a higher score among RRP+. Moreover, we do
not ﬁnd any difference concerning the part of the popu-
lation which fulﬁls the 2010 classiﬁcation criteria for RA.
Relevance of the determinants
The RRP predictors identiﬁed in the previously pub-
lished matrices were tested in the ESPOIR sDMARD
population (table 2). Substantial differences were noted
in terms of the statistical signiﬁcance of these predictors.
The presence of RF—or ACPAs, when tested—and
initial structural damage (qualitatively or quantitatively
assessed) were always predictive of RRP at 1 year.
However, DAS28 was not associated with RRP-positive
status, as compared with what was observed in the
SONORA cohort. C reactive protein (CRP) level and
RRP-positive status were associated signiﬁcantly with the
ASPIRE matrix thresholds, but the association did not
persist with the other matrices.
Likelihood of models with the ESPOIR cohort
According to the Bayesian information criterion, not sur-
prisingly, the more likely models were the mESPOIR
model (table 3). If we consider only models not devel-
oped on the ESPOIR population, we found that
SONORA seems to be the more likely model. We found
the same results when we analysed the pseudo-R2, with
the highest pseudo-R2 (0.2) for the mESPOIR model.
The Hosmer-Lemeshow test indicates the ﬁt of the
model to the data: all models had a poor ﬁt except for
the two ESPOIR models, which was predictable, and the
ASPIRE CRP model.
Performance of models with the ESPOIR cohort
The discriminative power of the matrices, determined by
receiver operating characteristic (ROC) analysis, is given
in ﬁgure 1 and table 3. The BEST and SONORA
Table 3 Likelihood and discriminative properties of different models
Model BIC
R2
Nagelkerke
Hosmer-
Lemeshow
test AUC (95% CI)
Mean predicted
probability
cases/non-cases
Integrated
discrimination
improvement
(p value)
ESPOIR 265.89 0.17 0.95910 0.75 (0.70 to 0.84) 0.20/0.10
mESPOIR 239.59 0.30 0.54740 0.82 (0.76 to 0.89) 0.29/0.09 −0.101 (p=0.3)
SONORA 264.55 0.00 0.00709 0.76 (0.68 to 0.83) 0.33/0.22 −0.008 (p=0.5)
SONORArecalculated 262.76 0.00 0.00019 0.76 (0.69 to 0.83) 0.06/0.04 0.079 (p=0.7)
BEST 1234.82 0.00 0.00023 0.73 (0.65 to 0.81) 0.90/0.78 −0.010 (p=0.5)
BESTrecalibrated 449.76 0.00 0.00008 0.73 (0.64 to 0.80) 0.61/0.40 −0.102 (p=0.4)
ASPIRE ESR 269.79 0.00 0.00635 0.54 (0.45 to 0.64) 0.17/0.15 0.091 (p=0.7)
ASPIRE ESRrecalibrated 464.10 0.00 0.00085 0.54 (0.46 to 0.64) 0.45/0.43 0.082 (p=0.6)
ASPIRE CRP 268.91 0.00 0.24880 0.62 (0.54 to 0.69) 0.21/0.18 0.067 (p=0.6)
ASPIRE CRPrecalibrated 574.03 0.00 0.00052 0.62 (0.41 to 0.60) 0.59/0.52 0.035 (p=0.6)
Integrated discrimination improvement is calculated as (average predicted probability cases—average predicted probability controls)new model—
(average predicted probability cases—average predicted probability controls)original ESPOIR model. A positive value indicates that the new model
provides an improvement over the original ESPOIR model.
AUC, area under the receiver operating characteristic curve; BIC, Bayesian Information Criterion; CRP, C reactive protein; ESR, erythrocyte
sedimentation rate.
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matrices showed interesting discriminative capacities
with the ESPOIR cohort, with AUC values of 0.73 and
0.76, respectively—close to that of the original ESPOIR
matrix. The ASPIRE CRP matrix showed only fair dis-
criminative capacity (0.62) and the ASPIRE erythrocyte
sedimentation rate (ESR) matrix only low capacity, with
an AUC close to 0.5.
In pairwise comparisons by the integrated discrimin-
ation improvement test (table 3), any model compared
with the ESPOIR model showed a signiﬁcantly larger dif-
ference in predicted probabilities between cases and
non-cases, which suggests no signiﬁcant better discrimin-
ation between cases and non-cases.
The discriminative power was analysed graphically by
evolution of the observed proportion of RRP according
to the predicted proportion of RRP by the matrix model,
stratiﬁed by quartiles (ﬁgures 2 and 3). As a general rule,
a clear gradient should be observed between these two
measurements, and as observed in ﬁgure 3, this is the
case for all matrices with the ESPOIR population, except
for the two ASPIRE matrices. Whatever the quartile of
predicted proportion of RRP estimated by the BEST
matrix, the predicted proportion of RRP in the ESPOIR
population was always relatively higher.
DISCUSSION
We assessed the performance of three matrix risk
models to predict RRP at 1 year in patients with early RA
despite csDMARD therapy. No matrix clearly showed
superior performance compared with the others. All
matrices could identify cases (RRP-positive) and non-
cases, but the ability was lower for matrices developed in
a clinical trial population, such as ASPIRE and BEST,
than those developed in a clinic-based RA population
such as SONORA.
One of the major strengths of the study is the use of
the ESPOIR population data,32 33 an early arthritis
cohort in which most of the participants had early RA
according to the 1987 American College of
Rheumatology (ACR) or 2010 ACR/European League
Against Rheumatism (ACR/EULAR) criteria.37 For this
study, we focused on patients receiving MTX within the
ﬁrst year of the disease, to be consistent with the trials
that were used for matrix development. We also
included patients receiving LEF, a drug of similar efﬁ-
cacy, which is recommended along with MTX as a ﬁrst-
line agent by all national or international clinical prac-
tice guidelines.2 9 For these reasons, the ESPOIR sample
perfectly corresponds to the target population of an
RRP matrix, that is, patients with early RA receiving
sDMARDs in real-life settings for whom assessing
whether such a therapy could be suboptimal in terms of
structural damage progression is highly relevant clinic-
ally. Compared with a previously published matrix valid-
ation study performed in an established RA population,27
our study appears more relevant. One other recent study
showed only fair performance of the matrices in a single
hospital-based early RA cohort; the small sample (n=74)
and the low number of RRP+ patients could explain the
difference of their results and ours.28
Figure 1 Performance on the different matrices with the
ESPOIR patients who initially received methotrexate or
leflunomide by ROC curve analysis. Data are area under the
ROC curve (95% CIs). AUC, area under the ROC curve; CRP,
C reactive protein; ROC, receiver operating characteristic.
Figure 2 Discriminative power of the two ESPOIR matrices.
The figure presents the observed proportions of rapid
radiographic progression (RRP) of rheumatoid arthritis by
groups of predicted probabilities of RRP for each model.
Groups were based on quartiles; error bars represent the 95%
CI. Value at the centre of the error bar represents the
observed proportion of RPP for a group. The mean predicted
proportion of RRP by group and the range are noted at the
bottom of the figure.
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Several statistics were used to compare models. There
are two major types of parameters: parameters assessing
the ﬁt and parameters assessing the discriminative power.
If the ESPOIR and mESPOIR matrices are set aside since
they have been developed on the same data as the valid-
ation cohort, the most adequate model was the SONORA
model with the parameter of ﬁt criteria, and the ASPIRE
model according the discrimnativ properties.
The performance of the matrices varied in the
ESPOIR population. Such variations might be explained
by several factors. First, the study population was an
unselected early RA population with a minimal level of
disease activity and no speciﬁc severity characteristics or
predictors required;32 33 this situation resulted in an
favourable outcome overall for most of the patients in
the ESPOIR cohort.38 As a consequence, the radio-
graphic structural progression in the ESPOIR population
was lower—mean 1.6 vSHS points—than in the MTX
arms for the SWEFOT, ASPIRE or BEST populations—
mean 2.7, 3.7 and 5, respectively.16 31 39
Another source of variation was the nature and framing
of the tested RRP determinants. Some just reﬂect disease
parameters at a certain point in time such as inﬂamma-
tion of clinical or biologic parameters, while others
reﬂect more disease intrinsic characteristics such as
erosion or autoantibody status. Expectedly, the predictive
performance of the latter is better than that of the former
at baseline Although ESR or CRP level, immunologic
status (presence of RF or ACPA) and baseline radio-
graphic ﬁndings were always present in the matrix, other
variables were not always present, especially swollen joint
count. Smoking status was present only in the SWEFOT
matrix;23 this determinant was not predictive of RRP in
the ESPOIR cohort and has even been associated with a
more favourable outcome and remission.40 The variable
framing is also a matter of variation. Baseline radio-
graphic characteristics were expressed qualitatively—
erosive disease or not—in some matrix tools. Although
interesting from a clinical perspective, the framing raises
the question of deﬁnition and reproducibility of the
notions of erosive disease or ‘typical RA erosion’, as men-
tioned in the 1987 ACR criteria. Recently, van der Heijde
et al41 proposed a deﬁnition of erosive disease in early RA
based on the number with erosive changes, namely >3
joints. The quantitative expression of structural damage
—number of erosions or vSHS value—has been used in
other matrix tools and appeared to be highly predictive of
further structural damage, with better AUC value and ﬁt
than matrices involving qualitative information. This
outcome was clearly expected according to the paradigm
‘who has eroded joints will have eroded joints’. However,
such quantitative assessment is not performed in daily
care, which limits the applicability of these RRP matrices
in daily practice.
In addition, the threshold used for each continuous
variable is questionable. Several methods have been
Figure 3 Discriminative power of the ASPIRE, BEST and SONORA matrices. The figure presents the observed proportions of
rapid radiographic progression (RRP) of rheumatoid arthritis by groups of predicted probabilities of RRP for each model. Groups
were based on quartiles; error bars represent the 95% CI. Value at the centre of the error bar represents the observed proportion
of RPP for a group. The mean predicted proportion of RRP by group and the range are noted at the bottom of the figure.
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used, mainly based on variable distributions, so pro-
posed matrices are too much tailored on the patient
population in which they were conceived. This is particu-
larly true for the matrices developed in an RCT popula-
tion. Another question which limits the applicability of
these RRP matrices in daily practice is that X-ray damage
is not even seen in 70% of MTX-treated patients, and
because X-ray damage is perhaps not the most relevant
outcome for patients, the RRP is not a relevant outcome
to try to predict. Perhaps we should focus on the predic-
tion of clinical response. However, we should think that
variables found to predict clinical response to MTX
treatment overlap with those associated with rapid pro-
gression. Furthermore, about 10% of patients got RRP
when treated with csDMARD monotherapy and hence
could beneﬁt from more intense therapy, such as combo
DMARDs or bDMARD. Thus, RRP is an important hall-
mark of aggressive or severe RA.
Potentially interesting determinants have not been
tested in the matrices developed to date. Proteomics of
genomic biomarkers, such as serum interleukin 6, metal-
loproteinases, shared epitope or eventually their com-
bination, were not included, although several studies
demonstrated their ability to predict disease severity.19
Recently, a for-proﬁt company proposed a commercial
kit of serum biomarkers associated with a patented spe-
ciﬁc algorithm, showing high correlation with disease
activity and severity.42 43 Although interesting at the
group level and for clinical research, the applicability
and cost-effectiveness of such a marketed biomarker kit
remains to be conﬁrmed.44
Finally, no matrix included early treatment response.
The ‘treat to target’ principle5 has been widely acknowl-
edged and is included in many clinical practice guide-
lines.2 This situation is reinforced by the results of
several trials involving dynamic therapeutic schemes—
step-up trials—which reported close efﬁcacy of MTX,
combination therapies or biologics for early RA.30 45 46
Several studies have shown that early therapeutic
response (ie, at 3 or 6 months) is highly predictive of
further treatment success or failure. The use of matrices
could help avoid MTX failure and be included in future
guidelines.
Matrices have limitations. The logistic regression
models from which they are derived provide estimates of
the probability of having a RRP at one year conditionally
of a combination of predictors for every single cell of
the matrix; however, since RRP is less frequent with
modern therapies, the right-top cells, corresponding to
the most at-risk categories, are usually weakly populated,
which results in wide CIs of the estimates. Such lack of
power deserves further research.
CONCLUSION
Matrices seem important to consider in optimising the
care of early RA by identifying patients who will respond
poorly to MTX. An alternative option could be biologic
agents; however, their place as ﬁrst-line RA therapy has
been ruled out by several economic evaluations report-
ing high incremental cost-effectiveness ratios largely
above the generally accepted thresholds.15 16 Yet another
option could be a combination of sDMARDs.9–11 Matrix
tools could be an adequate option to identify patients
with early RA at risk of inadequate response to MTX,
who could beneﬁt from more aggressive therapies such
as biologic agents, although for now the predicting per-
formance was modest. Although differences between
matrices are observed, this external validation study does
not allow one to state that one matrix is superior to the
others.
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